Physician profile
Arvind M Mahadevan
NPI 1114199148
$17,778.43
in general payments reported to CMS, 2019-2025
45 companies · $8,866 in 2025
The $8,866 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $1,577 · 2021: $2,033 · 2022: $1,462 · 2023: $1,403 · 2024: $1,308 · 2025: $8,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,503 · Food and Beverage: $4,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,502.71 |
| Food and Beverage | $4,075.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,524.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,103.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,338.75 | 2020-2025 | |
| Novo Nordisk INC | $1,031.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $835.93 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $597.50 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $483.77 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $343.17 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.34 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $298.58 | 2019-2025 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $296.44 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $265.52 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $254.33 | 2019-2022 | |
| Amarin Pharma, INC. | $229.90 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $212.75 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Mahadevan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.